Vanda Pharmaceuticals (VNDA) Current Assets (2010 - 2026)

Vanda Pharmaceuticals has disclosed Current Assets across 17 years of filings, most recently posting $293.2 million for Q1 2026.

• Current Assets for Q1 2026 came in at $293.2 million, down 28.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $293.2 million (down 28.13% YoY), and the FY2025 annual result was $347.3 million, down 20.88% from the prior year.
• Current Assets came in at $293.2 million for Q1 2026 at Vanda Pharmaceuticals, down from $347.3 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $536.6 million in Q3 2023 to a low of $293.2 million in Q1 2026.
• The 5-year median for Current Assets is $439.2 million (2024), against an average of $447.8 million.
• Across the five-year window, Current Assets advanced 16.87% in 2022 and fell 28.13% in 2026, its largest moves.
• Vanda Pharmaceuticals' Current Assets stood at $519.3 million in 2022, then declined by 16.63% to $432.9 million in 2023, then grew by 1.37% to $438.9 million in 2024, then declined by 20.88% to $347.3 million in 2025, then retreated by 15.58% to $293.2 million in 2026.
• The last three Current Assets figures came in at $293.2 million (Q1 2026), $347.3 million (Q4 2025), and $367.5 million (Q3 2025), per Business Quant data.